| 1 |
35419627 | An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. | 2022 May |
2 |
| 2 |
33669671 | Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells. | 2021 Feb 19 |
1 |
| 3 |
34761497 | MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways. | 2021 Dec |
1 |
| 4 |
31714594 | Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. | 2020 Feb 15 |
1 |
| 5 |
32388810 | TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer. | 2020 Jul |
1 |
| 6 |
33093458 | ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma. | 2020 Oct 22 |
1 |
| 7 |
30357520 | PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines. | 2019 Jan |
1 |
| 8 |
31438892 | Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer. | 2019 Aug 22 |
1 |
| 9 |
27055253 | Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. | 2016 |
1 |
| 10 |
27465688 | MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. | 2016 Jul 27 |
2 |
| 11 |
26124328 | Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib. | 2015 Jul |
1 |